Améliorer la mobilité après la revascularisation dans la maladie artérielle périphérique (IMPACT PAD)
Améliorer la mobilité après la revasCularisation dans la maladie artérielle périphérique : l'essai IMPACT PAD
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.
Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.
In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).
Aperçu de l'étude
Statut
Les conditions
Description détaillée
More than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for Medicare beneficiaries who have lower extremity peripheral artery disease (PAD) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, PAD related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.
Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization.
Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2). In Secondary Aims, the trial will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the Walking Impairment Questionnaire and the PROMIS Mobility Questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, the trial will test the effects of the interventions on plasma nitric oxide bioavailability. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling PAD.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Mary M McDermott, MD
- Numéro de téléphone: 312-503-6438
- E-mail: mdm608@northwestern.edu
Lieux d'étude
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85724
- Recrutement
- University of Arizona
-
Contact:
- Wei Zhou, MD
-
-
California
-
Downey, California, États-Unis, 90242
- Recrutement
- Rancho Research Institute
-
Contact:
- Tze-Woei Tan, MD
-
-
Florida
-
Tampa, Florida, États-Unis, 33606
- Recrutement
- University of South Florida
-
Contact:
- Ulka Sachdev, MD
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30307
- Recrutement
- Emory University School of Medicine
-
Contact:
- Olamide Alabi, MD
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
Contact:
- Tamar Polonsky, MD
- Numéro de téléphone: 773-702-6153
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern University Feinberg School of Medicine
-
Chercheur principal:
- Mary M McDermott, MD
-
Contact:
- Kathryn Domanchuk, BS
- Numéro de téléphone: 312-503-6438
- E-mail: k-domanchuk@northwestern.edu
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Health
-
Contact:
- Jonathan Ehrman, PhD
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03766
- Recrutement
- Dartmouth Hitchcock Medical Center
-
Contact:
- Philip P Goodney, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Successful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.
Exclusion Criteria:
- History of leg amputation, not including toe and partial foot amputation
- Active gangrene
- Active limb threatening ischemia
- Already exercising at a level consistent with exercise intervention, using investigator discretion.
- Unstable angina
- Unwilling to drink study beverages
- Unwilling to adhere to the interventions and complete follow-up testing
- Currently taking sildenafil, tadalafil, or related drugs.
- Unwilling to accept randomization into either group (home-based exercise or attention control)
- Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.
- History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
- Baseline blood pressure <100/45.
- Wheelchair confinement or requiring a walker to ambulate
- Walking is limited by a condition other than PAD
- Current foot ulcer
- Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months
- Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.
- Allergy to beetroot juice
- Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.
- Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.
- Visual impairment that limits walking ability.
- Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.
- Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
- Planning to begin a supervised treadmill exercise program in the next 12 months.
- Heart attack or stroke in previous three months prior to baseline testing.
- An eGFR value <30 or potassium >5.0.
- In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Home based exercise + nitrate rich beetroot juice
This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months. |
This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention Participants will drink one shot of nitrate rich beet-root juice twice daily for six months. |
|
Comparateur placebo: Home-based exercise + placebo
This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months. |
This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months. |
|
Expérimental: Attention control + nitrate-rich beetroot juice
This group will be participating in attention control and drinking nitrate rich beetroot juice for six months. |
Participants will drink one shot of nitrate rich beet-root juice twice daily for six months. Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D. |
|
Comparateur placebo: Attention control + placebo
This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months. |
Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months. Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Six-Minute Walk Distance 6-month change
Délai: Baseline to 6-month follow-up
|
Distance walked in six minutes |
Baseline to 6-month follow-up
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Walking Impairment Questionnaire (WIQ) Distance Score 6-month change
Délai: Baseline to 6-month follow-up.
|
Patient reported ability to walk long distances. Score Range 0-100, 100 is best. |
Baseline to 6-month follow-up.
|
|
Walking Impairment Questionnaire (WIQ) Distance Score 12-month change
Délai: Baseline to 12-month follow-up
|
Patient reported ability to walk long distances. Score Range 0-100, 100 is best. |
Baseline to 12-month follow-up
|
|
PROMIS Mobility Questionnaire Score 6-month change
Délai: Baseline to 6-month follow-up
|
Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome. |
Baseline to 6-month follow-up
|
|
PROMIS Mobility Questionnaire Score 12-month change
Délai: Baseline to 12-month follow-up.
|
Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome. |
Baseline to 12-month follow-up.
|
|
Prevention of Hemodynamic Failure of The Revascularized Vessel
Délai: Baseline to 12 month follow-up
|
Hemodynamic failure consists of loss of patency of the revascularized vessel. The outcome will be adjudicated as a categorical outcome. Medical records between randomization and final follow-up will be obtained and reviewed by the IMPACT PAD adjudication committee, consisting of field center investigators and an interventional cardiologist. Participants who meet pre-defined criteria for hemodynamic failure of the revascularized vessel. |
Baseline to 12 month follow-up
|
|
Change in 6-minute walk distance
Délai: 12 month follow-up
|
Change in 6-minute walk distance between baseline and 12-month follow-up |
12 month follow-up
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Six-Minute Walk Distance
Délai: Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
|
Change in six-minute walk distance 24 hours after the final study beverage |
Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
|
|
Plasma Nitrite Levels
Délai: Baseline to 6-month follow-up
|
Change in plasma nitrite levels in the blood at 6-month follow-up |
Baseline to 6-month follow-up
|
|
BH4/BH2 6-month change
Délai: Baseline to 6-month follow-up
|
Change in BH4/BH2 ratio |
Baseline to 6-month follow-up
|
|
Progression of PAD
Délai: Baseline to 12-month follow-up
|
Determine whether home-based walking exercise, compared to attention control prevents progression of PAD, defined by any new lower extremity revascularization, acute limb ischemia, or amputation of either lower extremity between baseline and 12-month follow-up. |
Baseline to 12-month follow-up
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Athérosclérose
- Artériosclérose
- Maladies artérielles occlusives
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Maladie artérielle périphérique
- Limitation de la mobilité
- Maladies vasculaires périphériques
- La claudication intermittente
- Produits chimiques organiques
- Produits chimiques inorganiques
- Composés d'azote
- Anions
- Ions
- Électrolytes
- Acide nitrique
- Nitrates
Autres numéros d'identification d'étude
- STU00222333
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Délai de partage IPD
Data will be available at the time the primary outcome manuscript is submitted for publication and will be available for up to 10 years.
Critères d'accès au partage IPD
Per BioLINCC
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .